-PTI/ Livemint.com * Being Health Minister of the country, how justified is it to release such falsely fabricated unscientific product, the IMA statement said * The IMA statement further said: Can you clarify the time frame, time line for the so-called clinical trial of this said anti-corona product The Indian Medical Association (IMA) on Monday said that it shocked over Patanjali Ayurveda's "blatant lie of WHO certification" for Coronil tablet, which the company...

-The Hindu They advise against Covaxin, say there is no proof of efficacy. Several experts have raised concern over the “hasty approval” granted to the COVID-19 vaccines despite the lack of adequate efficacy data. The Central Drugs Standard Control Organisation on Sunday accorded approval for restricted emergency use of the Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute of India (SII), and the indigenously developed vaccine Covaxin of Bharat Biotech. “I’m completely unaware...

-Livemint.com India has adopted a cautious approach in granting approval to covid-19 vaccines as fast tracking, safety and efficacy remain primary concern NEW DELHI: Safety and efficacy are the primary concerns of the government while granting emergency use authorization (EUA) to any covid-19 vaccine in the country. The government's cautious approach before approving a vaccine is apparent. The meeting of the subject expert committee of Central Drugs Standards Control Organisation on Wednesday asked...

-The Hindu CDSCO sends letter to manufacturers Alerted by the Union Health Ministry’s pharmaceutical watchdog, the National Co-ordination Centre of the Pharmacovigilance Programme of India (PvPI), on adverse reactions that were being reported from some commonly-used antibiotics, the Central Drugs Standard Control Organisation (CDSCO) has now asked manufacturers to ensure that this information be made available to the general public. CDSCO has written to drug manufacturers, to mention in leaflets inserted into drug...

-Hindustan Times With little transparency on how such deaths are investigated, and new rules relaxing how clinical trials are conducted in India, this data could be a poor estimate, said experts. Mumbai: At least 1,100 people who took part in clinical trials over the past four years have died, and 88 of these deaths were caused by direct side effects of the trials, the health ministry told the Rajya Sabha last week. But,...